Shares of aTyr Pharma Inc (NASDAQ:LIFE) have been assigned an average recommendation of “Hold” from the six brokerages that are presently covering the stock, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $1.01.
A number of analysts have weighed in on LIFE shares. ValuEngine cut aTyr Pharma from a “hold” rating to a “sell” rating in a research report on Tuesday, December 18th. Zacks Investment Research cut aTyr Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, January 16th. Finally, William Blair reaffirmed a “market perform” rating on shares of aTyr Pharma in a research report on Tuesday, March 26th.
Shares of NASDAQ LIFE traded up $0.01 during trading hours on Wednesday, reaching $0.56. The stock had a trading volume of 1,209 shares, compared to its average volume of 798,263. The stock has a market cap of $19.13 million, a PE ratio of -0.50 and a beta of 2.44. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.25. aTyr Pharma has a fifty-two week low of $0.38 and a fifty-two week high of $2.75.
A hedge fund recently raised its stake in aTyr Pharma stock. Renaissance Technologies LLC lifted its holdings in shares of aTyr Pharma Inc (NASDAQ:LIFE) by 107.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,107,025 shares of the biotechnology company’s stock after buying an additional 573,164 shares during the period. Renaissance Technologies LLC owned about 3.71% of aTyr Pharma worth $899,000 at the end of the most recent reporting period. 35.28% of the stock is owned by institutional investors and hedge funds.
About aTyr Pharma
aTyr Pharma, Inc, a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings.
Further Reading: What are catch-up contributions?
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.